The UK National Screening Committee’s (UKNSC) recent decision to reject an expanded prostate cancer screening programme has sparked criticism from medical experts and campaigners who question the composition and judgment of the committee responsible. Announced in May, the UKNSC recommendation limits screening to a small group of men aged 45 to 61 who have a rare gene mutation combined with a family history of certain cancers, effectively excluding the wider population, including those at higher risk.

Prostate cancer is the most common cancer among men in the UK, with approximately 63,000 new cases and 12,000 deaths annually. Unlike breast, bowel, and lung cancer, the disease currently lacks a national screening programme, a situation critics warn may contribute to avoidable deaths. Campaigners urge for a programme focused initially on high-risk groups, including men of Black African or Caribbean descent—who are statistically more likely to develop and die from prostate cancer—as well as those with a family history or specific genetic predispositions.

Central to the controversy is the fact that the UKNSC’s 13-member panel did not include any urologists, specialists directly involved in diagnosing and treating prostate cancer. Several retired and practising urologists have condemned the committee’s decision as based on outdated or flawed research, arguing that advances in diagnostic methods, such as PSA blood testing combined with modern MRI scans, allow for more accurate detection and can reduce unnecessary treatments. They contend that the committee’s concerns about false positives leading to overtreatment, and the associated risks of impotence and incontinence, do not reflect current clinical practice and patient preferences.

Critics also highlight the absence of any Black members on the committee, underscoring concerns that the disproportionate impact of prostate cancer on Black men was insufficiently considered. Sir Steve McQueen, an Oscar-winning director, called attention to this gap, suggesting that having members with personal or community experience of the disease would have influenced the decision.

The UKNSC maintains that its recommendation reflects a cautious approach, prioritising the principle that screening programmes must demonstrate more overall benefit than harm, given their application to asymptomatic populations. The committee and its administration emphasize the importance of avoiding unnecessary anxiety and medical interventions resulting from false positives or detection of slow-progressing cancers unlikely to cause harm. The panel’s chair, professor Sir Mike Richards, who has publicly shared his own prostate cancer experience, defended the decision as aligned with current scientific evidence.

The Department of Health and Social Care has accepted the UKNSC’s recommendation but confirmed that the committee’s guidance will remain under active review as new evidence emerges, including updated NHS diagnostic pathways that incorporate MRI before biopsy.

Nonetheless, campaigners and some medical professionals have called on Health Secretary James Murray to reconsider and potentially overrule the committee’s ruling, arguing that a broader screening initiative could save lives. Opponents of the decision urge a modernisation of the UKNSC’s approach, reflecting advances in prostate cancer diagnosis and treatment, patient autonomy, and the epidemiology of the disease. The debate underscores ongoing tensions between balancing public health policy caution and responding to evolving clinical evidence and community needs.